Long-term Compliance with Oral 5-aminosalicylic Acid Therapy and Risk of Disease Recurrence in Patients with Ulcerative Colitis: A Population-based Cohort Study

被引:9
|
作者
Prosberg, Michelle V. [1 ]
Vester-Andersen, Marianne K. [1 ]
Andersson, Mikael [2 ]
Jess, Tine [2 ]
Andersen, Jon T. [3 ]
Vind, Ida [1 ]
Bendtsen, Flemming [1 ]
机构
[1] Univ Copenhagen, Hvidovre Hosp, Gastrounit, Med Sect, Kettegaard Alle 30, DK-2650 Hvidovre, Denmark
[2] Natl Hlth Surveillance & Res, Dept Epidemiol Res, Copenhagen, Denmark
[3] Rigshosp, Dept Clin Pharmacol, DK-2100 Copenhagen, Denmark
关键词
ulcerative colitis; compliance; recurrence; INFLAMMATORY-BOWEL-DISEASE; MEDICATION NONADHERENCE; SURGERY RATES; MESALAZINE; MESALAMINE; ADHERENCE; DIAGNOSIS; PERSISTENCE; PREDICTORS; PHENOTYPE;
D O I
10.1097/MIB.0000000000000700
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background: Noncompliance to long-term medical therapy is a well-known problem among patients treated for ulcerative colitis, but studies of long-term consequences in unselected patients are lacking. The authors aimed to determine the risk of recurrence according to long-term compliance with oral 5-aminosalicylic acid among unselected patients with ulcerative colitis. Methods: The authors conducted a 7-year follow-up study of a population-based inception cohort of 243 Danish patients with ulcerative colitis diagnosed from 2003 to 2004. Compliance was defined as consumption of >= 80% of prescribed oral 5-aminosalicylic acid. Data were collected from medical records and the Danish National Prescription Database. They performed Cox regression analysis with adjustments for demographic and clinical characteristics to examine risk of recurrence (defined by increased use of oral 5-Aminosalicylic Acid, other additional treatment, or colectomy) in compliant versus noncompliant patients. Results: In total, 182 patients (75%) experienced at least 1 recurrence during follow-up. For the first year after diagnosis, risk of recurrence did not differ significantly between compliant and noncompliant patients. For 1 to 3 years (hazard ratio: 0.46, 95% CI, 0.33-0.63) and 3 to 8 years (hazard ratio: 0.42, 95% CI, 0.32-0.55) after diagnosis, risk of recurrence was significantly decreased among noncompliant patients compared with that of compliant patients. Conclusions: This unselected cohort study revealed a reverse association between compliance and recurrence of ulcerative colitis. This is unlikely to be explained by severe confounding because the authors were able to adjust for several demographic and clinical factors. Results may instead reflect that patients during recurrence-free periods through self-management choose not to take their medication.
引用
收藏
页码:925 / 932
页数:8
相关论文
共 50 条
  • [31] ANALYSIS OF ADHERENCE WITH ORAL 5-AMINOSALICYLIC ACID (5-ASA) THERAPY IN PATIENTS WITH ULCERATIVE COLITIS (UC) IN A UK PHARMACY DATABASE
    Hankins, M.
    Nedham, M.
    Jones, S.
    Yen, L.
    VALUE IN HEALTH, 2012, 15 (07) : A636 - A636
  • [32] Development of a Web-based concept for patients with ulcerative colitis and 5-aminosalicylic acid treatment
    Elkjaer, Margarita
    Burisch, Johan
    Avnstrom, Soren
    Lynge, Elsebeth
    Munkholm, Pia
    EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2010, 22 (06) : 695 - 704
  • [33] Increased Risk of Ulcerative Colitis in Patients with Periodontal Disease: A Nationwide Population-Based Cohort Study
    Lin, Chien-Yu
    Tseng, Kuo-Sen
    Liu, Jui-Ming
    Chuang, Heng-Chang
    Lien, Chi-Hone
    Chen, Yi-Chih
    Lai, Chun-Ying
    Yu, Cheng-Ping
    Hsu, Ren-Jun
    INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH, 2018, 15 (11)
  • [34] ORAL 5-AMINOSALICYLIC ACID (ASACOL) TOLERANCE VERSUS ORAL SULFASALAZINE TOLERANCE IN PATIENTS WITH CHRONIC ULCERATIVE-COLITIS
    TREMAINE, WJ
    SCHROEDER, KW
    GASTROENTEROLOGY, 1986, 90 (05) : 1670 - 1670
  • [35] 5-AMINOSALICYLIC ACID IN THE PREVENTION OF RELAPSES OF CROHNS-DISEASE IN REMISSION - A LONG-TERM STUDY
    BRESCI, G
    PETRUCCI, A
    BANTI, S
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY RESEARCH, 1991, 11 (04) : 200 - 202
  • [36] Long-term incidence of dysplasia and colorectal cancer in an ulcerative colitis population-based cohort
    Tranter-Entwistle, Isaac
    Mullaney, Tamara G.
    Noah, Kimberley
    Pearson, John
    Falvey, James
    Gearry, Richard
    Eglinton, Tim
    ANZ JOURNAL OF SURGERY, 2020, 90 (05) : 821 - 825
  • [37] 5-Aminosalicylic acid intolerance is associated with a risk of adverse clinical outcomes and dysbiosis in patients with ulcerative colitis
    Mizuno, Shinta
    Ono, Keiko
    Mikami, Yohei
    Naganuma, Makoto
    Fukuda, Tomohiro
    Minami, Kazuhiro
    Masaoka, Tatsuhiro
    Terada, Soichiro
    Yoshida, Takeshi
    Saigusa, Keiichiro
    Hirahara, Norimichi
    Miyata, Hiroaki
    Suda, Wataru
    Hattori, Masahira
    Kanai, Takanori
    INTESTINAL RESEARCH, 2020, 18 (01) : 69 - +
  • [38] No increased risk of nephrotoxicity associated with 5-aminosalicylic acid in IBD: a population-based cohort and nested case-control study
    Jairath, Vipul
    Hokkanen, Suvi R. K.
    Guizzetti, Leonardo
    Boxall, Naomi
    Campbell-Hill, Sarah
    Patel, Haridarshan
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2019, 50 (04) : 416 - 424
  • [39] Monitoring of Patients on Long-Term Glucocorticoid Therapy A Population-Based Cohort Study
    Fardet, Laurence
    Petersen, Irene
    Nazareth, Irwin
    MEDICINE, 2015, 94 (15)
  • [40] LONG-TERM MANAGEMENT OF REFRACTORY DISTAL ULCERATIVE-COLITIS (UC) WITH 5-AMINOSALICYLIC ACID (5-ASA) ENEMAS - LATE RESULTS
    VRANIAN, G
    CHATZINOFF, M
    FRIEDMAN, LS
    GASTROENTEROLOGY, 1988, 94 (05) : A483 - A483